Aurobindo Pharma’s arm receives USFDA approval for Amphotericin B Liposome for Injection.

18 Nov 2022 Evaluate

Aurobindo Pharma’s wholly owned subsidiary -- Eugia Pharma Specialities has received a final approval from the US Food & Drug Administration (USFDA) for Amphotericin B Liposome for Injection, 50 mg. Amphotericin B Liposome for Injection, 50 mg/vial Single-Dose Vial to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), AmBisome Liposome for Injection, 50 mg/vial, of Astellas Pharma US. The product is expected to be launched by Q4 FY23. The approved product has an estimated market size of around $145 million for the twelve months ending September 2022, according to IQVIA.

This is a partnership product from TTY Biopharm Company and will be manufactured at their Taiwan facility and marketed by Eugia Pharma. This is the 152nd ANDA (including 10 tentative approvals received) out of Eugia Pharma Speciality Group (EPSG) facilities, manufacturing both oral and sterile specialty products.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1177.10 8.20 (0.70%)
02-Feb-2026 15:32 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1629.00
Dr. Reddys Lab 1184.25
Cipla 1313.00
Zydus Lifesciences 877.15
Lupin 2124.10
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×